Angelman syndrome
Introduction
Angelman syndrome is a rare neurogenetic disorder affecting both cognitive and behavioral development. It is characterized by severe intellectual disability, minimal or absent speech, and difficulties with movement and balance. Individuals with this condition often display frequent laughing and a notably happy demeanor. The syndrome was first described by Harry Angelman in 1965. It is caused by abnormalities of the maternally inherited UBE3A gene located on 15q11–q13.
AS is part of a group of disorders known as genomic imprinting disorders. Other genomic imprinting disorders include Silver-Russell syndrome, Beckwith-Wiedemann syndrome, and Prader-Willi syndrome.
Affected individuals may also present with distinctive facial features, epilepsy, and sleep disturbances. Early diagnosis is important to ensure appropriate support and accurate genetic counseling for families.
Genetics
It is caused by a loss-of-function mutation in the maternally inherited UBE3A gene. This gene encodes an E3 ubiquitin ligase that is part of the ubiquitin–proteasome system and recognizes specific substrate proteins, attaching ubiquitin to them. This “tags” the proteins for degradation, usually by the proteasome. The paternal (father's) UBE3A gene is usually inactivated by a process called genomic imprinting, so if the maternal (mother's) gene is lost or nonfunctional, the body lacks a working copy. The most common cause is the maternal deletion of a region on chromosome 15 called 15q11-13, which happens in about 70% of cases.
Other causes include changes (mutations) in the UBE3A gene (10–20%), both copies of chromosome 15 coming from the father (paternal uniparental disomy, 2–5%), and problems with the imprinting process (3–5%). Rarely, other changes to chromosome 15 in this region can lead to the syndrome. Most cases occur by chance (sporadic inheritance), but some families pass on UBE3A mutations in an autosomal dominant pattern if the mother carries the mutation.
Pathophysiology
The pathophysiology of Angelman syndrome is characterized by a loss-of-function mutation in the UBE3A gene, which is expressed especially in hippocampal, cerebellar, and cortical neurons. The UBE3A gene controls synaptic protein degradation, neuronal plasticity, and neurotransmitter signaling. Its deficiency impairs synaptic function, disrupts cortical-cerebellar connectivity, and alters neural circuits. Resulting effects include defective long-term potentiation, disrupted GABAergic and glutamatergic signaling, and cerebellar dysfunction, contributing to cerebellar cognitive deficit, ataxia, and movement disorders. These neuronal changes cause severe developmental delay, absent speech, movement abnormalities, seizures, and a characteristic happy demeanor.
Epidemiology
It is a rare neurogenetic disorder, occurring in about 1 in 12,000 to 20,000 live births and affecting all sexes and ethnicities. Symptoms usually become apparent in the first year of life, and delayed developmental milestones with hypotonia, ataxia, and behavioral disabilities often raise early clinical suspicion. While most cases arise sporadically, familial recurrence may occur in families carrying UBE3A mutations or imprinting defects.
Clinical Manifestations
Angelman syndrome presents with a combination of neurological, behavioral, and physical abnormalities. Neurologically, patients have severe psychomotor developmental delay. They have minimal or absent speech, hypotonia, ataxia, tremulous limb movements, and gait instability. Refractory seizures often begin before age three. Seizures may be generalized tonic-clonic, atypical absence, or myoclonic. Microcephaly usually develops in early childhood. Children often show frequent laughing, smiling, excitability, hand flapping, hyperactivity, and a short attention span.
Physical features include a wide mouth, prominent chin, deep-set eyes, and an upturned nose. Sometimes, scoliosis is also present. Sleep disturbances and feeding difficulties are common. In Angelman syndrome, cerebellar dysfunction is a hallmark that often leads to hypotonia, ataxic gait, and tremulous limb movements. Consequently, affected individuals typically exhibit poor balance, clumsiness, and delayed motor milestones, all of which result from impaired coordination.
Diagnosis
Diagnosis is based on clinical signs and EEG results, then confirmed by DNA testing. Physicians should consider Angelman syndrome in children with major delays in development, no speech, movement issues, typical behaviors, and seizures. Neuroimaging is often normal, but may show slight shrinkage of the cerebellum or cortex. EEG often shows large, slow spike wave patterns. The final diagnosis depends on genetic testing. These tests check for missing pieces or imprinting problems on chromosome 15q11-q13, errors in the UBE3A gene, and uniparental disomy using SNP or microarray analysis. Similar conditions to consider are Rett syndrome, Pitt-Hopkins syndrome, and Prader-Willi syndrome.
Treatment
There is no curative therapy for AS. Management is based on supportive and symptomatic treatment. Seizures are managed with antiepileptic drugs according to seizure type. Examples of AEDs include valproate, clobazam, clonazepam, or levetiracetam. In refractory epilepsy, the ketogenic diet or VNS (vagus nerve stimulation) may also be indicated.
Developmental support includes early intervention with physical, occupational, and speech therapy. However, augmentative and alternative communication devices are also used. Behavioral support focuses on structured routines to manage hyperactivity. Sleep problems may be improved by sleep hygiene strategies or medications, including melatonin, antihistamines, or benzodiazepines. Orthopedic management includes monitoring for scoliosis and providing devices for gait instability. Genetic counseling is important for discussing recurrence risk and reproductive options.
Prognosis
Angelman syndrome is a lifelong and incurable disorder with severe cognitive and motor impairment. Most people survive into adulthood, and seizures often become stable and improve successively with age. Mobility and communication skills remain limited; however, the characteristic happiness and sociable personality persist. Life expectancy is generally near normal but comorbidities like uncontrolled seizures, obesity, or orthopedic problems can affect overall health. Supportive therapies and multidisciplinary care help patients achieve their fullest potential despite developmental challenges.
